Press release
Persistent corneal epithelial defects Pipeline Analysis, 2025 | PCEDs Clinical Trials | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma
Persistent corneal epithelial defects Pipeline Analysis
DelveInsight's Persistent corneal epithelial defects Clinical Trials Analysis Report provides deep insights to support strategic decision-making for Persistent corneal epithelial defects pipeline expansion, competitive positioning, and partnership identification in the rare neurodegenerative disease space.
Persistent corneal epithelial defects (PCEDs) Overview:
The cornea, the transparent outer layer of the eye, is essential for vision as it bends most incoming light evenly toward the lens. Its layered epithelial surface not only protects against infections through tightly linked cells but also preserves a smooth optical surface by continually regenerating basal cells. Persistent Corneal Epithelial Defects (PCEDs)-also referred to as PEDs-arise when the corneal surface fails to heal within 10-14 days after injury, even with appropriate supportive care. Such defects can compromise both the epithelial and stromal layers, leaving the eye susceptible to infections, stromal ulcers, perforation, scarring, and serious vision loss.
Download our report @ https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Persistent corneal epithelial defects (PCEDs) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Persistent corneal epithelial defects (PCEDs) Therapeutics Market.
Key Takeaways from the Persistent corneal epithelial defects (PCEDs) Pipeline Report
*
DelveInsight's Persistent Corneal Epithelial Defects (PCEDs) Pipeline Report highlights a dynamic landscape, with over 5 companies actively developing 5+ therapeutic candidates for PCEDs.
*
In April 2023, the FDA granted Fast Track designation to KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy developed by Kala Pharmaceuticals. This designation is intended to accelerate the development and review of therapies addressing serious conditions with unmet medical needs. KPI-012 is currently being assessed in the Phase 2b CHASE trial, targeting PCEDs arising from multiple causes, including neurotrophic keratitis and chemical injuries. Early study findings demonstrated encouraging safety outcomes, and Kala expects to release top-line safety and efficacy data in Q1 2024.
*
Leading companies in the PCEDs space include Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, among others, all working to advance innovative therapies. Prominent emerging candidates include KPI-012, Nexagon, and more, reflecting significant progress in improving the PCEDs treatment landscape.
Persistent corneal epithelial defects (PCEDs) Pipeline Analysis
The Persistent corneal epithelial defects (PCEDs) pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Persistent corneal epithelial defects (PCEDs) Market.
*
Categorizes Persistent corneal epithelial defects (PCEDs) therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Persistent corneal epithelial defects (PCEDs) drugs under development based on:
*
Stage of development
*
Persistent corneal epithelial defects (PCEDs) Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Persistent corneal epithelial defects (PCEDs) Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Persistent corneal epithelial defects (PCEDs) Licensing agreements
*
Funding and investment activities supporting future Persistent corneal epithelial defects (PCEDs) market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Persistent corneal epithelial defects (PCEDs) Emerging Drugs
*
KPI-012: Kala Pharmaceuticals
Kala Pharmaceuticals is developing KPI-012 for the treatment of persistent corneal epithelial defect (PCED), a rare disorder that impairs corneal healing. The company is also investigating its potential in other rare front-of-eye diseases, including partial limbal stem cell deficiency and moderate-to-severe Sjogren's syndrome. Currently in a Phase II clinical trial slated for completion in February 2024, KPI-012 is derived from a proprietary mesenchymal stem cell secretome (MSC-S) platform. Kala advanced this program following its acquisition of Combangio, Inc. in November 2021.
*
Nexagon: Eyevance/Amber Ophthalmics
NEXAGON is a first-in-class, unmodified antisense oligodeoxynucleotide that targets connexin43 (Cx43), a membrane protein upregulated following injury or in chronic disease. Excess Cx43 triggers abnormal hemichannel opening, leading to ATP release and activation of inflammatory pathways that drive vessel leakage and limbal ischemia. By blocking Cx43, NEXAGON helps reduce inflammation, repair limbal microvasculature, and promote regeneration of the corneal epithelium.
Major trends shaping the clinical trial and competitive landscape for Persistent corneal epithelial defects:
*
Shift Toward Regenerative Therapies: Increasing focus on stem cell-based therapies, growth factors, and biologics to promote corneal healing.
*
Emergence of Novel Drug Modalities: Development of antisense oligonucleotides, gene therapies, and nanosuspensions targeting underlying disease mechanisms.
*
Expansion of Clinical Trials: Growth in early- and mid-stage trials exploring multiple therapeutic approaches, including combination therapies.
*
Strategic Collaborations: Partnerships between biotech, pharma, and academic institutions to accelerate R&D and share technological expertise.
*
Regulatory Support: Orphan Drug, Fast Track, and RMAT designations facilitate expedited development for rare ocular disorders.
*
Patient-Centric Approaches: Incorporation of patient-reported outcomes, corneal healing metrics, and visual function assessments in clinical studies.
*
Innovation in Formulations and Delivery: Focus on ocular nanosuspensions, topical applications, and controlled-release systems to improve efficacy and compliance.
*
Competitive Differentiation: Companies differentiating pipelines by mechanism of action, stage of development, and molecular type.
*
Real-World Evidence Integration: Leveraging real-world data and observational studies to support clinical development and market adoption.
Persistent corneal epithelial defects (PCEDs) Companies
More than five key companies are actively working on therapies for Persistent Corneal Epithelial Defects (PCEDs), with several candidates already advancing into Phase II clinical trials.
DelveInsight's report covers around 5+ products under different phases of Persistent corneal epithelial defects (PCEDs) clinical trials like
*
Persistent corneal epithelial defects (PCEDs) Late stage Therapies (Phase III)
*
Persistent corneal epithelial defects (PCEDs) Mid-stage Therapies (Phase II)
*
Persistent corneal epithelial defects (PCEDs) Early-stage Therapies (Phase I)
*
Persistent corneal epithelial defects (PCEDs) Pre-clinical and Persistent corneal epithelial defects (PCEDs) Discovery stage Therapies
*
Persistent corneal epithelial defects (PCEDs) Discontinued & Inactive Therapies
Persistent corneal epithelial defects (PCEDs) pipeline report provides the Persistent corneal epithelial defects (PCEDs) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Persistent corneal epithelial defects (PCEDs) Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Persistent corneal epithelial defects (PCEDs) Therapies and Key Persistent corneal epithelial defects (PCEDs) Companies: Persistent corneal epithelial defects (PCEDs) Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Persistent corneal epithelial defects (PCEDs) Pipeline Therapeutic Assessment
- Persistent corneal epithelial defects (PCEDs) Assessment by Product Type
- Persistent corneal epithelial defects (PCEDs) By Stage
- Persistent corneal epithelial defects (PCEDs) Assessment by Route of Administration
- Persistent corneal epithelial defects (PCEDs) Assessment by Molecule Type
Persistent corneal epithelial Report Section Includes:
*
Persistent corneal epithelial competitive landscape clinical trials
*
Persistent corneal epithelial emerging drugs analysis
*
Persistent corneal epithelial investigational drugs report
*
Persistent corneal epithelial clinical trial trends analysis
*
Persistent corneal epithelial pipeline benchmarking report
*
Persistent corneal epithelial drug pipeline competitive intelligence
*
Persistent corneal epithelial competitive landscape
Download Persistent corneal epithelial defects (PCEDs) Sample report to know in detail about the Persistent corneal epithelial defects (PCEDs) treatment market @ Persistent corneal epithelial defects (PCEDs) Therapeutic Assessment [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Persistent corneal epithelial defects (PCEDs) Current Treatment Patterns
4. Persistent corneal epithelial defects (PCEDs) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Persistent corneal epithelial defects (PCEDs) Late-Stage Products (Phase-III)
7. Persistent corneal epithelial defects (PCEDs) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Persistent corneal epithelial defects (PCEDs) Discontinued Products
13. Persistent corneal epithelial defects (PCEDs) Product Profiles
14. Persistent corneal epithelial defects (PCEDs) Key Companies
15. Persistent corneal epithelial defects (PCEDs) Key Products
16. Dormant and Discontinued Products
17. Persistent corneal epithelial defects (PCEDs) Unmet Needs
18. Persistent corneal epithelial defects (PCEDs) Future Perspectives
19. Persistent corneal epithelial defects (PCEDs) Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Persistent corneal epithelial defects (PCEDs) Pipeline Reports Offerings [https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=persistent-corneal-epithelial-defects-pipeline-analysis-2025-pceds-clinical-trials-eyevance-amber-ophthalmics-kala-pharmaceuticals-noveome-biotherapeutics-oyster-point-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent corneal epithelial defects Pipeline Analysis, 2025 | PCEDs Clinical Trials | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma here
News-ID: 4174560 • Views: …
More Releases from ABNewswire
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
Prominent Criminal Lawyer in Galveston Firm Celebrates 25+ Years of Texas Gulf C …
Tad Nelson & Associates celebrates over 25 years of criminal defense excellence across the Texas Gulf Coast, combining local roots, community involvement, and personalized legal services that span multiple counties.
A prominent Texas law firm has reached a significant milestone, celebrating over 25 years of providing criminal defense and family law services across the Greater Houston area and Galveston County. The achievement underscores the firm's steadfast commitment to serving Texas communities…
More Releases for Persistent
Evolving Market Trends In The Advanced Persistent Threat Protection Industry: In …
The Advanced Persistent Threat Protection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Advanced Persistent Threat Protection Market Size During the Forecast Period?
The market size for advanced persistent threat protection has seen a substantial increase in the recent past. It is…
Advanced Persistent Threat Protection Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Advanced Persistent Threat Protection Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The Advanced Persistent Threat (APT) Protection market is experiencing significant growth due to the increasing frequency and sophistication of cyberattacks. APTs are long-term,…
Decentralized Identity Systems Market Dynamics and Demand A Deep Dive into Trend …
The Decentralized Identity Systems Market is an emerging and transformative sector within the blockchain and digital identity industries, offering a secure and user-centric approach to managing identity information. Decentralized identity systems empower individuals to have more control over their personal data and digital identities, reducing reliance on centralized entities for identity verification. These systems utilize blockchain technology and cryptography to provide secure, privacy-enhancing, and interoperable solutions for identity management. As…
Global Advanced Persistent Threat Protection Market
The data examined by GME predicted that by 2026, the Global Advanced Persistent Threat Protection Market would grow with a CAGR value of 19.5 percent. External threats are constantly on the lookout for opportunities to hack security networks and obtain access to sensitive data. Hence, with the rising cases of cyber security thefts or crime will help propel the market from 2021 to 2026. Moreover the market is projected to…
Pyrometer Market Expansion to be Persistent During 2028
Pyrometer Market – Notable Developments
In April 2019, AMETEK Land revealed its enhanced SPOT infrared pyrometer software packages, SPOTPro and SPOTViewer. The newly launched pyrometer packages are aimed at giving users a better understand of the performance of various processes and aid them in realizing industry 4.0 connectivity.
In December 2018, Extech announced launch of a ruggedized, dual-laser infrared (IR) thermometer named IR320, which is designed to perform rough and tough jobs…
DevSecOps Market Expansion to be Persistent during 2023
Overview:
In the recent times, a new trend is gaining popularity in the software development life cycle called DevSecOps. This technology bridges the gap between development, operations, and security teams to speed up the software development process through collaboration and communication among the teams. The goal of DevOps is to give more ownership to the development team for developing and monitoring applications. Security plays a key role by providing high-end security…
